Clinical Research Directory

Inclusion Criteria: * Key Inclusion Criteria * Subjects with histologically or cytologically documented NSCLC. * Locally advanced or metastatic ROS1 fusion positive NSCLC. * Prior one or two ROS1-TKI(s) Treatment. * World Health Organization (WHO) performance status 0-1. * Life expectancy of at least 3 months. * At least one measurable lesion according to RECISIT 1.1. Exclusion Criteria: * Key Exclusion Criteria: * Current participation in another therapeutic clinical trial. * Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption. * A history of severe allergies, or a history of severe allergy, hypersensitivity or other hypersensitivity to any active or inactive ingredient of the study drug. * All acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 Grade more than 1. * Any investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment. * Known active infe